Drug intelligence / Profile preview

LucenBS

Development stage: Phase 3
Lead developer: Samsung Bioepis
Modality: Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Ophthalmic, Intravitreal

Overview

LucenBS is an ophthalmic biosimilar product referencing ranibizumab (Lucentis), an anti‑VEGF biologic used to treat neovascular (wet) age‑related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, and other choroidal neovascular conditions. Ranibizumab is a recombinant humanized IgG1 kappa monoclonal antibody fragment that binds vascular endothelial growth factor A (VEGF‑A), preventing its interaction with VEGF receptors VEGFR1 and VEGFR2 on endothelial cells, thereby inhibiting pathological angiogenesis, vascular leakage, and macular edema in the retina.[1][3][7]

Brand names: LucenBS

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on LucenBS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LucenBS.

Explore the full profile